Innoviva, Inc.
General ticker "INVA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B (TTM average)
Innoviva, Inc. follows the US Stock Market performance with the rate: 0.3%.
Estimated limits based on current volatility of 1.4%: low 18.20$, high 18.76$
Factors to consider:
- Total employees count: 159 (+25.2%) as of 2025
- Top business risk factors: Market competition, Regulatory and compliance, R&D failure, Acquisition/divestiture risks, Key person loss
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [14.74$, 22.41$]
- 2026-12-31 to 2027-12-31 estimated range: [15.19$, 22.98$]
Short-term INVA quotes
Long-term INVA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $310.46MM | $358.71MM | $411.33MM |
| Operating Expenses | $196.58MM | $191.84MM | $247.58MM |
| Operating Income | $113.89MM | $166.87MM | $163.75MM |
| Non-Operating Income | $80.21MM | $-129.48MM | $163.12MM |
| Interest Expense | $19.16MM | $22.21MM | $16.70MM |
| R&D Expense | $33.92MM | $13.65MM | $30.60MM |
| Income(Loss) | $194.10MM | $37.39MM | $326.86MM |
| Taxes | $14.38MM | $14.00MM | $55.70MM |
| Net Income(Loss)* | $179.72MM | $23.39MM | $271.17MM |
| Stockholders Equity | $674.96MM | $691.16MM | $1,172.84MM |
| Inventory | $40.74MM | $33.73MM | $39.17MM |
| Assets | $1,243.51MM | $1,301.06MM | $1,635.16MM |
| Operating Cash Flow | $141.06MM | $188.69MM | $196.93MM |
| Capital expenditure | $0.41MM | $0.27MM | $10.50MM |
| Investing Cash Flow | $-66.76MM | $-63.79MM | $40.50MM |
| Financing Cash Flow | $-171.84MM | $-13.45MM | $8.55MM |
| Earnings Per Share** | $2.75 | $0.37 | $4.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.